Encompass Health Corporation $EHC Stock Position Increased by Bahl & Gaynor LLC

Encompass Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bahl & Gaynor increased its Encompass Health stake by 25% in the third quarter, adding 184,230 shares to reach 921,908 shares valued at about $112 million. Institutional investors collectively own 97.25% of the stock.
  • Analysts maintain a broadly positive outlook: the consensus rating is Buy, with an average price target of $154.25.
  • Encompass Health beat quarterly earnings expectations, reporting $1.52 per share versus a $1.36 estimate, while revenue rose 8.9% year over year to $1.61 billion.
  • MarketBeat previews top five stocks to own in December.

Bahl & Gaynor LLC increased its holdings in Encompass Health Corporation (NYSE:EHC - Free Report) by 25.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 921,908 shares of the company's stock after buying an additional 184,230 shares during the period. Bahl & Gaynor LLC owned 0.93% of Encompass Health worth $112,003,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Transamerica Financial Advisors LLC purchased a new stake in shares of Encompass Health during the second quarter worth $29,000. Persistent Asset Partners Ltd bought a new position in shares of Encompass Health in the second quarter worth $36,000. Toth Financial Advisory Corp purchased a new position in shares of Encompass Health in the third quarter valued at $38,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Encompass Health in the second quarter valued at $39,000. Finally, Assetmark Inc. raised its stake in shares of Encompass Health by 89.6% during the 1st quarter. Assetmark Inc. now owns 455 shares of the company's stock valued at $44,000 after purchasing an additional 215 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EHC shares. UBS Group increased their price objective on Encompass Health from $155.00 to $165.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Barclays raised their target price on Encompass Health from $144.00 to $151.00 and gave the stock an "overweight" rating in a research note on Thursday, October 29th. Wall Street Zen raised Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. Weiss Ratings upgraded Encompass Health from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $155.00 price target on shares of Encompass Health in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $154.25.

Get Our Latest Analysis on Encompass Health

Encompass Health Stock Up 1.1%

Shares of NYSE:EHC opened at $142.68 on Wednesday. The firm has a fifty day moving average price of $125.54 and a two-hundred day moving average price of $111.36. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.09 and a quick ratio of 1.09. Encompass Health Corporation has a one year low of $92.77 and a one year high of $143.36. The company has a market cap of $14.00 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 2.45 and a beta of 0.83.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.16. The firm had revenue of $1.61 billion for the quarter, compared to analysts' expectations of $1.60 billion. Encompass Health had a net margin of 10.17% and a return on equity of 18.35%. The business's quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.23 earnings per share. Analysts anticipate that Encompass Health Corporation will post 6.29 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Monday, January 4th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, January 4th. Encompass Health's dividend payout ratio is currently 13.12%.

Insiders Place Their Bets

In other Encompass Health news, EVP John Darby sold 4,858 shares of the firm's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $121.09, for a total value of $588,255.22. Following the sale, the executive vice president owned 75,041 shares of the company's stock, valued at $9,086,714.69. This trade represents a 6.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.80% of the stock is owned by corporate insiders.

Encompass Health Company Profile

(Free Report)

Encompass Health Corporation is a U.S. healthcare provider focused on inpatient rehabilitation. The company operates rehabilitation hospitals that offer specialized care for people recovering from conditions such as strokes, brain and spinal cord injuries, orthopedic conditions, and other illnesses or injuries. Its hospitals provide coordinated rehabilitation services, including physical, occupational, and speech therapy, alongside medical care. Encompass Health serves patients through facilities across the United States.

Further Reading

Institutional Ownership by Quarter for Encompass Health (NYSE:EHC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Encompass Health Right Now?

Before you consider Encompass Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.

While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines